New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS inhibitors

Current Treatment Options in Neurology

Volumn 14, Issue 1, 2012, Pages 50-59

  Hoffmann, Jan ^a   Goadsby, Peter J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BI 44370 TA; Calcitonin gene related peptide; CGRP receptor antagonists; Drug therapy; Gepants; GW274150; iNOS inhibitors; Migraine; Olcegepant; Pathophysiology; Prophylaxis; Telcagepant; Treatment

Indexed keywords

BI 44370 TA; BIBN 4096 BS; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCITONIN RECEPTOR LIKE RECEPTOR; ELETRIPTAN; MK 3207; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; OLCEGEPANT; PLACEBO; RIZATRIPTAN; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; SUMATRIPTAN; TELCAGEPANT; UNCLASSIFIED DRUG;

ARTICLE; ASTHENIA; BLOOD PRESSURE; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; LIVER TOXICITY; MIGRAINE; MIGRAINE WITH AURA; MYALGIA; NOCICEPTION; NONHUMAN; PARESTHESIA; PATHOPHYSIOLOGY; SIDE EFFECT; THORAX PAIN; THROAT TIGHTNESS; TRIGEMINAL NUCLEUS; TRIGEMINUS GANGLION;

EID: 84857633644     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-011-0155-4     Document Type: Article

References (76)

1. L Stovner K Hagen R Jensen, et al. 2007 The global burden of headache: a documentation of headache prevalence and disability worldwide Cephalalgia 27 3 193 210 17381554 (Pubitemid 46354128)
2. M Menken TL Munsat JF Toole 2000 The global burden of disease study: implications for neurology Arch Neurol 57 3 418 420 10714674 1:STN:280:DC%2BD3c7nslWmtA%3D%3D (Pubitemid 30140537)
3. BK Rasmussen R Jensen M Schroll J Olesen 1991 Epidemiology of headache in a general population-a prevalence study J Clin Epidemiol 44 11 1147 1157 1941010 1:STN:280:DyaK38%2FksVKlsw%3D%3D
4. SD Silberstein RB Lipton 1996 Headache epidemiology. Emphasis on migraine Neurol Clin 14 2 421 434 8827180 1:STN:280:DyaK28visVOiuw%3D%3D
5. AI Scher WF Stewart J Liberman RB Lipton 1998 Prevalence of frequent headache in a population sample Headache 38 7 497 506 15613165 1:STN:280:DC%2BD2cnjslCnsQ%3D%3D (Pubitemid 28429337)
6. RB Lipton AI Scher K Kolodner, et al. 2002 Migraine in the United States: epidemiology and patterns of health care use Neurology 58 6 885 894 11914403 1:STN:280:DC%2BD387ot1Wqtw%3D%3D (Pubitemid 34242063)
7. MS Robbins RB Lipton 2010 The epidemiology of primary headache disorders Semin Neurol 30 2 107 119 20352581
8. MD Ferrari KI Roon RB Lipton PJ Goadsby 2001 Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials Lancet 358 9294 1668 1675 11728541 1:CAS:528:DC%2BD3MXos1ajsro%3D (Pubitemid 33124324)
9. TW Ho L Edvinsson PJ Goadsby 2010 CGRP and its receptors provide new insights into migraine pathophysiology Nat Rev Neurol 6 10 573 582 20820195 1:CAS:528:DC%2BC3cXht1Gku7bI
10. PJ Goadsby 2009 The vascular theory of migraine - a great story wrecked by the facts Brain 132 Pt 1 6 7 19098031
11. HC Diener 1999 Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group Cephalalgia 19 6 581 588 10448545 1:STN:280:DyaK1MznslKmtg%3D%3D (Pubitemid 29362813)
12. V Limmroth A May H Diener 1999 Lysine-acetylsalicylic acid in acute migraine attacks Eur Neurol 41 2 88 93 10023111 1:CAS:528:DyaK1MXisVOltbg%3D (Pubitemid 29089973)
13. MW Weatherall AJ Telzerow E Cittadini, et al. 2010 Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache Neurology 75 12 1098 1103 20855853 1:CAS:528:DC%2BC3cXhtFOrsbjK This trial demonstrates the efficacy and safety of intravenous lysine acetylsalicylate in patients hospitalized with severe headache due to abrupt medication withdrawal.
14. HC Diener P Barbanti C Dahlof, et al. 2011 BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study Cephalalgia 31 5 573 584 21172952 This phase II trial demonstrates the efficacy of the CGRP receptor antagonist BI 44370 TA in the treatment of acute migraine attacks.
15. TW Ho MD Ferrari DW Dodick, et al. 2008 Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial Lancet 372 9656 2115 2123 19036425 1:CAS:528:DC%2BD1cXhsFajs7nE
16. TW Ho LK Mannix X Fan, et al. 2008 Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine Neurology 70 16 1304 1312 17914062 1:CAS:528:DC%2BD1cXktlOhtLs%3D (Pubitemid 351550355)
17. J Olesen HC Diener IW Husstedt, et al. 2004 Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine N Engl J Med 350 11 1104 1110 15014183 1:CAS:528:DC%2BD2cXitV2qur0%3D (Pubitemid 38298990)
18. DL Nelson LA Phebus KW Johnson, et al. 2010 Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan Cephalalgia 30 10 1159 1169 20855361
19. AJ Pilgrim B Dussault NMJ Rupniak, et al. 2009 COL-144, an orally bioavailable selective 5-HT1F receptor agonist for acute migraine therapy Cephalalgia 29 24 25
20. J Olesen 2010 5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks Cephalalgia 30 10 1157 1158 20855360
21. 1F agonist lasmiditan in acute migraine attacks. Efficacy was demonstrated for doses of 20-45 mg.
22. V Limmroth A May P Auerbach, et al. 1996 Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine J Neurol Sci 138 1-2 60 65 8791240 1:CAS:528:DyaK28Xkslymtro%3D (Pubitemid 26194276)
23. SG Amara V Jonas MG Rosenfeld, et al. 1982 Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products Nature 298 5871 240 244 6283379 1:CAS:528:DyaL3sXkslynuw%3D%3D (Pubitemid 12089405)
24. SJ Wimalawansa 1996 Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials Endocr Rev 17 5 533 585 8897024 1:CAS:528:DyaK28XmvF2hs7Y%3D (Pubitemid 26346642)
25. J Tajti R Uddman S Moller, et al. 1999 Messenger molecules and receptor mRNA in the human trigeminal ganglion J Auton Nerv Syst 76 2-3 176 183 10412842 1:CAS:528:DyaK1MXjs1SnsL4%3D (Pubitemid 29322040)
26. S Eftekhari CA Salvatore A Calamari, et al. 2010 Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion Neuroscience 169 2 683 696 20472035 1:CAS:528:DC%2BC3cXos1ymt7Y%3D
27. L Edvinsson S Gulbenkian CP Barroso, et al. 1998 Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility Peptides 19 7 1213 1225 9786171 1:CAS:528:DyaK1cXmsVygs7c%3D (Pubitemid 28475125)
28. T Hokfelt U Arvidsson S Ceccatelli, et al. 1992 Calcitonin gene-related peptide in the brain, spinal cord, and some peripheral systems Ann N Y Acad Sci 657 119 134 1637079 1:STN:280:DyaK38zksVamsg%3D%3D
29. D van Rossum UK Hanisch R Quirion 1997 Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors Neurosci Biobehav Rev 21 5 649 678 9353797 (Pubitemid 27458805)
30. V Limmroth Z Katsarava B Liedert, et al. 2001 An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system Pain 92 1-2 101 106 11323131 1:CAS:528: DC%2BD3MXivFehurw%3D (Pubitemid 32367941)
31. N Offenhauser T Zinck J Hoffmann, et al. 2005 CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion Cephalalgia 25 3 225 236 15689199 1:STN:280:DC%2BD2M%2FmtVyquw%3D%3D (Pubitemid 40321716)
32. RJ Storer S Akerman PJ Goadsby 2004 Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat Br J Pharmacol 142 7 1171 1181 15237097 1:CAS:528:DC%2BD2cXmvFKqt7Y%3D (Pubitemid 39093014)
33. PJ Goadsby 2007 Recent advances in understanding migraine mechanisms, molecules and therapeutics Trends Mol Med 13 1 39 44 17141570 1:CAS:528:DC%2BD2sXis1Crtw%3D%3D (Pubitemid 46027728)
34. PJ Goadsby L Edvinsson 1993 The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats Ann Neurol 33 1 48 56 8388188 1:STN:280:DyaK3s3mtlGqsw%3D%3D (Pubitemid 23009909)
35. PJ Goadsby L Edvinsson R Ekman 1990 Vasoactive peptide release in the extracerebral circulation of humans during migraine headache Ann Neurol 28 2 183 187 1699472 1:STN:280:DyaK3M%2FisVSktQ%3D%3D (Pubitemid 20244522)
36. PJ Goadsby L Edvinsson R Ekman 1988 Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system Ann Neurol 23 2 193 196 2454066 1:CAS:528: DyaL1cXhsVeqsLo%3D (Pubitemid 18081459)
37. LH Lassen PA Haderslev VB Jacobsen, et al. 2002 CGRP may play a causative role in migraine Cephalalgia 22 1 54 61 11993614 1:STN:280: DC%2BD383ltlGrtA%3D%3D (Pubitemid 34626025)
38. J Olesen LL Thomsen H Iversen 1994 Nitric oxide is a key molecule in migraine and other vascular headaches Trends Pharmacol Sci 15 5 149 153 7538702 1:CAS:528:DyaK2cXksl2ltbs%3D (Pubitemid 24156497)
39. N Aiyar K Rand NA Elshourbagy, et al. 1996 A cDNA encoding the calcitonin gene-related peptide type 1 receptor J Biol Chem 271 19 11325 11329 8626685 1:CAS:528:DyaK28XivV2isLY%3D (Pubitemid 26155969)
40. LM McLatchie NJ Fraser MJ Main, et al. 1998 RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor Nature 393 6683 333 339 9620797 1:CAS:528:DyaK1cXjsFyjt78%3D (Pubitemid 28269699)
41. W Ma JG Chabot KJ Powell, et al. 2003 Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems Neuroscience 120 3 677 694 12895509 1:CAS:528:DC%2BD3sXlvVCltb4%3D (Pubitemid 36928066)
42. S Eftekhari L Edvinsson 2010 Possible sites of action of the new calcitonin gene-related peptide receptor antagonists Ther Adv Neurol Disord 3 6 369 378 21179597 1:CAS:528:DC%2BC3MXpslCg
43. KR Oliver A Wainwright L Edvinsson, et al. 2002 Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature J Cereb Blood Flow Metab 22 5 620 629 11973435 1:CAS:528:DC%2BD38XktlWgsLs%3D (Pubitemid 34477784)
44. JK Lennerz V Ruhle EP Ceppa, et al. 2008 Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution J Comp Neurol 507 3 1277 1299 18186028 1:CAS:528:DC%2BD1cXjt1Sltbc%3D (Pubitemid 351413572)
45. MD Ferrari PJ Goadsby KI Roon RB Lipton 2002 Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials Cephalalgia 22 8 633 658 12383060 1:STN:280:DC%2BD38njtlehtw%3D%3D (Pubitemid 36609333)
46. KM Connor RE Shapiro HC Diener, et al. 2009 Randomized, controlled trial of telcagepant for the acute treatment of migraine Neurology 73 12 970 977 19770473 1:CAS:528:DC%2BD1MXhtFantLfE This randomized, double-blind, placebo-controlled phase III trial demonstrates the efficacy of MK-0974 for the treatment of acute migraine attacks.
47. L Edvinsson TW Ho 2010 CGRP receptor antagonism and migraine Neurotherapeutics 7 2 164 175 20430315 1:CAS:528:DC%2BC3cXntlOnurw%3D
48. C Sur R Hargreaves I Bell, et al. 2009 CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer Cephalalgia 29 Suppl 1 136 137
49. AP Ho CG Dahlof SD Silberstein, et al. 2010 Randomized, controlled trial of telcagepant over four migraine attacks Cephalalgia 30 12 1443 1457 20974601 This clinical trial demonstrates consistency of the efficacy of MK-0974 in multiple migraine attacks.
50. TW Ho J Olesen DW Dodick, et al. 2011 Antimigraine efficacy of telcagepant based on patient's historical triptan response Headache 51 1 64 72 21054362 This study indicates that triptan nonresponders may benefit from the CGRP receptor antagonists.
51. T Ho K Connor C Dahlof, et al. 2009 Assessment of the long term safety and tolerability of telcagepant for the intermittent treatment of acute migraine: a double-blind, active-controlled study Cephalalgia 29 Suppl 1 12
52. KM Connor SK Aurora T Loeys, et al. 2011 Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial Headache 51 1 73 84 21070230
53. TH Han RL Blanchard J Palcza, et al. 2010 Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults J Clin Pharmacol 50 12 1367 1376 20173082 1:CAS:528:DC%2BC3cXhsFyqs7bI
54. Merck, Merck Updates Status of Clinical Development Programs for Investigational CGRP Receptor Antagonist Treatments for Acute Migraine; MK-3207 Clinical Development Discontinued, Sept. 10, 2009, http://www.merck.com/ newsroom/news-release-archive/research-and-development/2009-0910.html (Accessed May 10, 2011).
55. CA Salvatore EL Moore JC Hershey, et al. 2009 Pharmacological characterization of MK-3207, a potent and orally bioavailable CGRP receptor anagonist Cephalalgia 29 Suppl 1 139
56. DJ Hewitt SK Aurora DW Dodick, et al. 2011 Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine Cephalalgia 31 6 712 722 21383045
57. KY Chan L Edvinsson S Eftekhari, et al. 2010 Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries J Pharmacol Exp Ther 334 3 746 752 20573757 1:CAS:528:DC%2BC3cXhtFyksL%2FM
58. R De Col SV Koulchitsky KB Messlinger 2003 Nitric oxide synthase inhibition lowers activity of neurons with meningeal input in the rat spinal trigeminal nucleus Neuroreport 14 2 229 232 12598735 (Pubitemid 36308416)
59. C Tassorelli SA Joseph 1995 Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat Brain Res 682 1-2 167 181 7552308 1:CAS:528:DyaK2MXmtVymsr0%3D
60. GA Lambert KL Hoskin AS Zagami 2004 Nitrergic and glutamatergic neuronal mechanisms at the trigeminovascular first-order synapse Neuropharmacology 47 1 92 105 15165837 1:CAS:528:DC%2BD2cXksVagtb0%3D (Pubitemid 38686314)
61. MG Jones I Lever S Bingham, et al. 2001 Nitric oxide potentiates response of trigeminal neurones to dural or facial stimulation in the rat Cephalalgia 21 6 643 655 11531896 1:STN:280:DC%2BD3MvovFCitQ%3D%3D (Pubitemid 32762787)
62. KL Hoskin DC Bulmer PJ Goadsby 1999 Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME Neurosci Lett 266 3 173 176 10465701 1:CAS:528:DyaK1MXjsVSgtLg%3D (Pubitemid 29249243)
63. S Akerman DJ Williamson H Kaube PJ Goadsby 2002 Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels Br J Pharmacol 137 1 62 68 12183331 1:CAS:528:DC%2BD38XmslClt7g%3D (Pubitemid 34983464)
64. Q Lin J Palecek V Paleckova, et al. 1999 Nitric oxide mediates the central sensitization of primate spinothalamic tract neurons J Neurophysiol 81 3 1075 1085 10085334 1:CAS:528:DyaK1MXitFCms70%3D (Pubitemid 29272425)
65. J Olesen HK Iversen LL Thomsen 1993 Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain Neuroreport 4 8 1027 1030 8241457 1:CAS:528:DyaK2cXhs1SlsLY%3D (Pubitemid 23242637)
66. Headache Classification Subcommittee of the International Headache Society 2004 The International Classification of Headache Disorders: 2nd edition Cephalalgia 24 Suppl 1 9 160
67. I Christiansen LL Thomsen D Daugaard, et al. 1999 Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura Cephalalgia 19 7 660 667 10524660 1:STN:280:DyaK1Mvlt1aqsw%3D%3D (Pubitemid 29465917)
68. S Koulchitsky MJ Fischer R De Col, et al. 2004 Biphasic response to nitric oxide of spinal trigeminal neurons with meningeal input in rat-possible implications for the pathophysiology of headaches J Neurophysiol 92 3 1320 1328 15115784 1:CAS:528:DC%2BD2cXnvVams7c%3D (Pubitemid 39100634)
69. SK Afridi H Kaube PJ Goadsby 2004 Glyceryl trinitrate triggers premonitory symptoms in migraineurs Pain 110 3 675 680 15288408 1:CAS:528:DC%2BD2cXmt1WrsLo%3D (Pubitemid 39036799)
70. LH Lassen M Ashina I Christiansen, et al. 1997 Nitric oxide synthase inhibition in migraine Lancet 349 9049 401 402 9033475 1:STN:280: DyaK2s7osFOqtg%3D%3D (Pubitemid 27077677)
71. J Olesen 2010 Nitric Oxide-related drug targets in headache Neurotherapeutics 7 2 183 190 20430317 1:CAS:528:DC%2BC3cXntlOnuro%3D
72. WK Alderton ADR Angell C Craig, et al. 2005 GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo Brit J Pharmacol 145 3 301 312 1:CAS:528:DC%2BD2MXks1Gntbs%3D (Pubitemid 40896075)
73. J De Alba NM Clayton SD Collins, et al. 2006 GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (NOS), shows analgesic effects in rat models of inflammatory and neuropathic pain Pain 120 1-2 170 181 16360270 (Pubitemid 43077180)
74. JE Palmer FL Guillard BE Laurijssens, et al. 2009 A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine Cephalalgia 29 124 This phase II trial with 75 participants demonstrated that despite high potency and selectivity, the iNOS inhibitor GW274150 is not effective in the acute treatment of migraine.
75. HO Hoivik BE Laurijssens LO Harnisch, et al. 2010 Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache Cephalalgia 30 12 1458 1467 20974604 This double-blind, placebo-controlled phase II trial demonstrates that the daily administration of 60 mg or 120 mg of the iNOS inhibitor GW274150 is not effective in migraine prophylaxis.
76. K Høye 2009 LB, Harnisch LO, Twomey CK, Dixon RM, Kirkham, Williams PM, Wentz AL. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine Cephalalgia 29 132